Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Price

Showing results (1-10 of 153) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|March 21, 2018
Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancerTimothy J Price
The Lancet. Oncology|January 18, 2017
Advanced colorectal cancer treatment options beyond standard systemic therapyTimothy J Price
The Lancet. Oncology|April 17, 2015
Second-line therapy for metastatic colorectal cancerTimothy J Price
Ebiomedicine|May 8, 2019
Moving miRNAs to therapeutic targets in colorectal cancerMark McGregor, Timothy J Price
Future Oncology (London, England)|May 9, 2018
Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRCMark McGregor, Timothy J Price
Archives of Surgery (Chicago, Ill. : 1960)|March 19, 2008
Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastasesTimothy J Price, Amanda Townsend
Expert Review of Anticancer Therapy|December 15, 2015
Optimal therapy for resectable rectal cancerSubotheni Thavaneswaran, Timothy J Price
Annals of Translational Medicine|February 13, 2020
IMblaze 370: lessons learned and future strategies in colorectal cancer treatmentMark McGregor, Timothy J Price
Expert Opinion on Biological Therapy|February 24, 2018
Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potentialGonzalo Tapia Rico, Timothy J Price
Therapeutic Advances in Gastroenterology|January 2, 2014
Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancerChristopher M Hocking, Timothy J Price
Pageof 16

Showing results (1-10 of 153) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|March 21, 2018
Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancerTimothy J Price
The Lancet. Oncology|January 18, 2017
Advanced colorectal cancer treatment options beyond standard systemic therapyTimothy J Price
The Lancet. Oncology|April 17, 2015
Second-line therapy for metastatic colorectal cancerTimothy J Price
Ebiomedicine|May 8, 2019
Moving miRNAs to therapeutic targets in colorectal cancerMark McGregor, Timothy J Price
Future Oncology (London, England)|May 9, 2018
Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRCMark McGregor, Timothy J Price
Archives of Surgery (Chicago, Ill. : 1960)|March 19, 2008
Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastasesTimothy J Price, Amanda Townsend
Expert Review of Anticancer Therapy|December 15, 2015
Optimal therapy for resectable rectal cancerSubotheni Thavaneswaran, Timothy J Price
Annals of Translational Medicine|February 13, 2020
IMblaze 370: lessons learned and future strategies in colorectal cancer treatmentMark McGregor, Timothy J Price
Expert Opinion on Biological Therapy|February 24, 2018
Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potentialGonzalo Tapia Rico, Timothy J Price
Therapeutic Advances in Gastroenterology|January 2, 2014
Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancerChristopher M Hocking, Timothy J Price
Pageof 16